These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 10463532)

  • 1. Bioassays and biological stability.
    Wright JF
    Dev Biol Stand; 1999; 97():73-80. PubMed ID: 10463532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of bioassays for the characterisation and control of biological therapeutic products produced by biotechnology.
    Thorpe R; Wadhwa M; Mire-Sluis A
    Dev Biol Stand; 1997; 91():79-88. PubMed ID: 9413686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioassays for the characterisation and control of therapeutic cytokines; determination of potency.
    Thorpe R; Wadhwa M; Page C; Mire-Sluis A
    Dev Biol Stand; 1999; 97():61-71. PubMed ID: 10463531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parameters for the evaluation of IL-2 stability.
    Kenney WC; Watson E; Bartley T; Boone T; Altrock BW
    Lymphokine Res; 1986; 5 Suppl 1():S23-7. PubMed ID: 3491260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of potency for well characterized biotechnology proteins.
    Finbloom DS
    Dev Biol Stand; 1998; 96():63-4. PubMed ID: 9890518
    [No Abstract]   [Full Text] [Related]  

  • 6. [Peptide mapping analysis of recombinant human interleukin-11 with HPLC-ESI-Q-TOF/MS spectrometry].
    Yang Y; Rao CM; Wang W; Han CM; Wang JZ
    Yao Xue Xue Bao; 2006 Aug; 41(8):756-60. PubMed ID: 17039783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of assay validation in specification development.
    Baffi RA
    Dev Biol Stand; 1997; 91():105-13. PubMed ID: 9413687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of an in vitro potency assay for therapeutic TGFbeta antagonists: the A549 cell bioassay.
    Rapoza ML; Fu D; Sendak RA
    J Immunol Methods; 2006 Oct; 316(1-2):18-26. PubMed ID: 17010369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tools to evaluate the conformation of protein products.
    Manta B; Obal G; Ricciardi A; Pritsch O; Denicola A
    Biotechnol J; 2011 Jun; 6(6):731-41. PubMed ID: 21567963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of bioassays in the assessment of recombinant proteins.
    Jeffcoate SL
    Dev Biol Stand; 1994; 83():159-64. PubMed ID: 7883090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of standard and state of the art analytical technology-bioassays.
    Indelicato SR; Bradshaw SL; Chapman JW; Weiner SH
    Dev Biol (Basel); 2005; 122():103-14. PubMed ID: 16375255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and validation of a quantitative cell-based bioassay for comparing the pharmacokinetic profiles of two recombinant erythropoietic proteins in serum.
    Wei X; Grill DS; Heatherington AC; Swanson SJ; Gupta S
    J Pharm Biomed Anal; 2007 Jan; 43(2):666-76. PubMed ID: 16971087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of an in vitro potency bioassay for therapeutic IL-13 antagonists: the A-549 cell bioassay.
    Miller R; Sadhukhan R; Wu C
    J Immunol Methods; 2008 May; 334(1-2):134-41. PubMed ID: 18355834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An improved bioassay for the detection of Bacillus thuringiensis beta-exotoxin.
    Mac Innes TC; Bouwer G
    J Invertebr Pathol; 2009 Jun; 101(2):137-9. PubMed ID: 19358852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein ligation: an enabling technology for the biophysical analysis of proteins.
    Muralidharan V; Muir TW
    Nat Methods; 2006 Jun; 3(6):429-38. PubMed ID: 16721376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Scientific rationale for the replacement of an in vivo bioassay for protein drugs with a physico-chemical assay].
    Hayakawa T
    Eisei Shikenjo Hokoku; 1994; (112):202-3. PubMed ID: 8854933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinase Receptor Activation (KIRA): a rapid and accurate alternative to endpoint bioassays.
    Sadick MD
    Dev Biol Stand; 1999; 97():121-33. PubMed ID: 10463538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring of glycoprotein products in cell culture lysates using lectin affinity chromatography and capillary HPLC coupled to electrospray linear ion trap-Fourier transform mass spectrometry (LTQ/FTMS).
    Wang Y; Wu SL; Hancock WS
    Biotechnol Prog; 2006; 22(3):873-80. PubMed ID: 16739974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipidomic analysis of signaling pathways.
    Wakelam MJ; Pettitt TR; Postle AD
    Methods Enzymol; 2007; 432():233-46. PubMed ID: 17954220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complementary mass spectrometric techniques to achieve complete sequence coverage of recombinant human tropoelastin.
    Getie M; Schmelzer CE; Weiss AS; Neubert RH
    Rapid Commun Mass Spectrom; 2005; 19(20):2989-93. PubMed ID: 16178053
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.